NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus, enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming levodopa’s biggest deficiency – a short half-life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

AAN 2018, LA – Oral presentation Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients.

AAN 2018, LA – Oral presentation Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients.

NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in cash. MTPC is a publicly traded company on the Tokyo Stock Exchange

NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in cash. MTPC is a publicly traded company on the Tokyo Stock Exchange

Our Solutions

NeuroDerm is developing products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients.
NeuroDerm is the first company to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed LD/CD products administered through a patch-pump or small belt pump, designed to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612 as a low dose and a high dose for moderate to severe Parkinson’s disease patients.